Federal Panel Rules to Keep Mirena Migraine Lawsuits Separate

Thursday, August 28, 2014

So far, nearly 1,000 women have filed lawsuits over the popular IUD contraceptive Mirena after suffering serious uterus perforations that required surgery.

Now, a growing number of lawsuits over a different issue indicate the birth control insert from Bayer may have other dangers as well.

Several new federal lawsuits filed in different states allege the hormone levonorgestrel used in Mirena may cause a serious neurological disorder called PTC, or pseudotumor cerebri.

PTC can cause ongoing problems such as migraines, hearing problems and vision loss.

Levonorgestrel has been linked to PTC and intracranial hypertension for decades, however there are no formal warnings yet issued. Bayer, the maker of Mirena, has not warned patients or doctors about a risk of PTC from the device.

Other Mirena cases for uterine perforation have been consolidated to one federal court for more efficient handling. This month, a panel of judges considered whether to do the same for the growing number of migraine/vision loss cases.

However, in a surprise decision, the court ruled that the plaintiffs and device maer are better served by keeping the cases located in their present courts.

This means those injured by vision loss after using Mirena can file an injury lawsuit in the court closest to their location.



Other drugs and devices in the news:

Friday, August 9, 2019
Surgical Stapler
Did Surgical Staple Companies Hide Thousands of Injuries?

This past spring, the FDA issued a warning affecting the millions of patients each year that undergo routine gastrointestinal, gynecologic...

Friday, August 2, 2019
Invokana Gangrene Amputation
Federal Panel Adds Fournier's Gangrene to Crowded Invokana MDL Court

In the latest Invokana lawsuit update, DrugNews has learned that a federal judicial panel has transferred new cases alleging...

Get in touch with us.

Call, email or live chat with us today to see how we can help.

call DrugNews.net
Need a quick answer? Call us!
email DrugNews.net
Reach out to us by email.
live chat with DrugNews
We are here to help now